Tel Aviv Sourasky Medical Center Chooses SOPHiA DDMTM HRD Solution of SOPHiA GENETICS

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)-- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Tel Aviv Sourasky Medical Center (Ichilov), the largest acute care facility in Israel, has chosen to use SOPHiA DDM™ to enhance its genetic testing capabilities. The facility, which serves a population of one million people, will use the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution to help advance its clinical oncology research.

HRD is caused by a cell’s impaired ability to repair DNA double-stranded breaks through the homologous recombination repair (HRR) pathway and is a common feature of high-grade serous ovarian cancer (HGSOC) as well as breast, prostate, and pancreatic cancers. For those diagnosed with these cancer types, HRD can be used as a potential predictive biomarker for therapy response.

The SOPHiA DDM^TM HRD Solution provides a unique approach to molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples. By implementing SOPHiA DDM^TM HRD Solution, Tel Aviv Sourasky Medical Center (Ichilov) will have the opportunity to identify larger populations of individuals with HRD-positive cancer who may benefit from treatment with PARP inhibitors (PARPi).

“The implementation of methods able to detect HRD is crucial for identifying patients who could benefit from treatment with PARPi,” said Dr. Ariel Erental, Tel Aviv Sourasky Medical Center. “The SOPHiA DDM^TM HRD Solution will help to inform data-driven decisions that advance the clinical research at Tel Aviv Sourasky Medical Center into HRD-associated cancers.”

SOPHiA DDM^TM HRD Solution enables laboratories and healthcare institutions to identify HRR mutations and measure genomic instability via a decentralized approach. This approach to HRD testing for tumor samples allows the users to retain full ownership of their data, saving time and expense, while offering comprehensive genomic insights powered by deep learning algorithms.

“SOPHiA GENETICS is working to make data-driven medicine more broadly accessible to patients around the globe,” said Ken Freedman, Chief Revenue Officer, SOPHiA GENETICS. “By implementing SOPHiA DDM^TM HRD Solution, Tel Aviv Sourasky Medical Center will have access to high analytical performance and streamlined bioinformatics workflows, making it more efficient to detect HRD status in advanced ovarian cancer and other relevant cancers.”

In addition to supporting Tel Aviv Sourasky Medical Center in its work to detect HRD status in select cancers, the powerful analytics of SOPHiA DDM^TM HRD Solution will help the Medical Center maximize in-house genomic insights to help advance its clinical research capabilities.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230404005766/en/